Qiang Zhao

Director/Board Member presso Shanghai Haihe Biopharma Co., Ltd.

61 anni

Utilities

Commercial Services

Producer Manufacturing

Profilo

Qiang Zhao is an Independent Director at Shanghai Haihe Biopharma Co., Ltd.
since 2020.
Prior to this, he held the position of Independent Director at Jionto Energy Investment Co., Ltd.
Hebei.
He also served as an Independent Director at Beijing Chieftain Control Engineering Technology Co., Ltd.
from 2017 to 2023.

Posizioni attive di Qiang Zhao

Società	Posizione	Inizio
Shanghai Haihe Biopharma Co., Ltd. Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.	Director/Board Member	08/09/2020

Tutte le posizioni attive di Qiang Zhao

Precedenti posizioni note di Qiang Zhao

Società	Posizione	Fine
BEIJING CHIEFTAIN CONTROL ENGINEERING TECHNOLOGY CO., LTD.	Director/Board Member	10/06/2023
JOINTO ENERGY INVESTMENT CO., LTD. HEBEI	Director/Board Member	-

Vedi nel dettaglio l'esperienza di Qiang Zhao

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Qiang Zhao

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
JOINTO ENERGY INVESTMENT CO., LTD. HEBEI	Utilities
BEIJING CHIEFTAIN CONTROL ENGINEERING TECHNOLOGY CO., LTD.	Producer Manufacturing

Aziende private	1
Shanghai Haihe Biopharma Co., Ltd. Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China.	Commercial Services